Stock A950210 PRESTIGE BIOPHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prestige BioPharma Limited

Equities

A950210

KR8702070002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
7,980 KRW 0.00% Intraday chart for Prestige BioPharma Limited -1.60% -15.82%
2023 Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer CI
2023 Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit CI

Valuation

Fiscal Period: June 2021 2022 2023
Capitalization 1 396,635 137,620 113,582
Enterprise Value (EV) 1 -54,947 -161,400 -103,457
P/E ratio -230 x -3.02 x 32.3 x
Yield - - -
Capitalization / Revenue - - 701,810,622 x
EV / Revenue - - -639,252,890 x
EV / EBITDA 3.29 x 1.36 x -8.16 x
EV / FCF 2,459,475 x 1,409,329 x -12,706,238 x
FCF Yield 0% 0% -0%
Price to Book 17.2 x 8 x 6.3 x
Nbr of stocks (in thousands) 12,019 12,019 12,019
Reference price 2 33,000 11,450 9,450
Announcement Date 21-09-16 22-09-20 23-09-18
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2020 2021 2022 2023
Net sales - - - 161.8
EBITDA 1 -11,708 -16,717 -118,822 12,684
EBIT 1 -12,893 -18,384 -122,689 1,034
Operating Margin - - - 639.01%
Earnings before Tax (EBT) 1 -14,898 -7,357 -210,649 -2,095
Net income 1 -14,997 -7,391 -211,450 17,569
Net margin - - - 10,855.89%
EPS 2 -351.6 -143.2 -3,796 292.4
Free Cash Flow - -22,341 -114,523 8,142
FCF margin - - - 5,031.02%
FCF Conversion (EBITDA) - - - 64.19%
FCF Conversion (Net income) - - - 46.34%
Dividend per Share - - - -
Announcement Date 21-09-16 21-09-16 22-09-20 23-09-18
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: June 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 45,521 451,582 299,020 217,039
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -22,341 -114,523 8,142
ROE (net income / shareholders' equity) - -2.07% -42.1% -0.59%
ROA (Net income/ Total Assets) - -3.01% -13.9% 0.1%
Assets 1 - 245,807 1,522,144 16,877,319
Book Value Per Share 2 3,082 1,913 1,431 1,499
Cash Flow per Share 2 1,028 1,527 894.0 416.0
Capex 1 1,340 949 56,429 48,363
Capex / Sales - - - 29,882.73%
Announcement Date 21-09-16 21-09-16 22-09-20 23-09-18
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
PRESTIGE BIOPHARMA LIMITED Stock Prestige BioPharma Limited
-15.82% 70.29M
CSL LIMITED Stock CSL Limited
-1.26% 89.46B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.74B
BIOGEN INC. Stock Biogen Inc.
-9.06% 33.03B
UCB Stock UCB
+55.32% 24.68B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.61% 15.12B
INCYTE CORPORATION Stock Incyte Corporation
-9.14% 12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.11% 11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.61% 11.64B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.79% 8.9B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A950210 Stock
  4. Financials Prestige BioPharma Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW